Compare MNY & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | ATNM |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 45.2M |
| IPO Year | N/A | N/A |
| Metric | MNY | ATNM |
|---|---|---|
| Price | $1.24 | $1.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | $4.00 |
| AVG Volume (30 Days) | 51.0K | ★ 134.6K |
| Earning Date | 12-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,182,746.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.55 | $1.03 |
| 52 Week High | $2.40 | $2.41 |
| Indicator | MNY | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 36.80 |
| Support Level | $1.26 | $1.27 |
| Resistance Level | $1.27 | $1.38 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 3.70 |
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.